Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CORTOTCMKTS:EVTCYNASDAQ:INDVNASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORTCorcept Therapeutics$70.90+1.2%$71.49$28.04▼$117.33$7.43B0.191.14 million shs806,952 shsEVTCYEvotec$4.27-3.8%$3.96$14.22▼$26.57$1.41B0.982,407 shs35,297 shsINDVIndivior$14.18+2.1%$11.30$7.33▼$16.98$1.96B0.661.10 million shs1.14 million shsNUVLNuvalent$76.32-2.5%$73.10$55.54▼$113.51$5.48B1.34492,720 shs523,650 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORTCorcept Therapeutics0.00%+0.66%-6.69%+21.04%+141.84%EVTCYEvotec0.00%+5.43%+8.38%+21.65%-6.15%INDVIndivior0.00%-1.28%+22.49%+39.04%-15.97%NUVLNuvalent0.00%+0.28%+6.71%+1.58%+0.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORTCorcept Therapeutics4.6557 of 5 stars3.51.00.04.23.34.21.9EVTCYEvotecN/AN/AN/AN/AN/AN/AN/AN/AINDVIndivior2.7244 of 5 stars1.65.00.00.03.81.71.9NUVLNuvalent2.3409 of 5 stars3.52.00.00.02.23.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORTCorcept Therapeutics 3.00Buy$138.2594.99% UpsideEVTCYEvotec 0.00N/AN/AN/AINDVIndivior 3.25Buy$15.005.78% UpsideNUVLNuvalent 2.90Moderate Buy$115.5051.34% UpsideCurrent Analyst Ratings BreakdownLatest EVTCY, CORT, NUVL, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$135.005/6/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$150.00 ➝ $145.004/3/2025CORTCorcept TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.004/1/2025CORTCorcept TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $142.003/31/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$76.00 ➝ $150.003/31/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$115.00 ➝ $150.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORTCorcept Therapeutics$685.45M10.97$1.04 per share67.96$4.92 per share14.41EVTCYEvotec$572.16M2.46$0.04 per share105.53$2.52 per share1.69INDVIndivior$1.17B1.67$2.87 per share4.94N/A∞NUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORTCorcept Therapeutics$106.14M$1.1656.2738.32N/A22.35%24.54%20.24%8/4/2025 (Estimated)EVTCYEvotec$7.14M$0.4110.41∞N/A20.85%16.02%7.81%N/AINDVIndivior$2M-$0.31N/A8.29N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)NUVLNuvalent-$126.22M-$4.39N/AN/AN/AN/A-28.63%-27.15%8/14/2025 (Estimated)Latest EVTCY, CORT, NUVL, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORTCorcept TherapeuticsN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORTCorcept Therapeutics0.013.703.64EVTCYEvotec0.532.572.50INDVIndiviorN/A0.830.65NUVLNuvalentN/A23.0723.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORTCorcept Therapeutics93.61%EVTCYEvotecN/AINDVIndivior60.33%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipCORTCorcept Therapeutics20.80%EVTCYEvotecN/AINDVIndiviorN/ANUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORTCorcept Therapeutics300106.05 million83.30 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableINDVIndivior1,164137.88 millionN/ANot OptionableNUVLNuvalent4071.81 million62.16 millionOptionableEVTCY, CORT, NUVL, and INDV HeadlinesRecent News About These CompaniesNuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stockJune 15 at 12:03 PM | investing.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 15 at 1:34 AM | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 200 SharesJune 11, 2025 | insidertrades.comInsider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 200 Shares of StockJune 10, 2025 | marketbeat.comNuvalent Board Member Emily Conley ResignsJune 10, 2025 | tipranks.comCalifornia State Teachers Retirement System Purchases 5,109 Shares of Nuvalent, Inc. (NASDAQ:NUVL)June 6, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Nuvalent, Inc. (NASDAQ:NUVL)June 2, 2025 | marketbeat.comNuvalent, Inc. Reports Q1 2025 Financial ResultsMay 31, 2025 | tipranks.comNuvalent (NASDAQ:NUVL) Stock Price Up 6.2% - Time to Buy?May 30, 2025 | marketbeat.comSquarepoint Ops LLC Reduces Position in Nuvalent, Inc. (NASDAQ:NUVL)May 29, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Polar Asset Management Partners Inc.May 28, 2025 | marketbeat.comVoloridge Investment Management LLC Has $13.37 Million Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 26, 2025 | marketbeat.comTwo Sigma Advisers LP Decreases Stake in Nuvalent, Inc. (NASDAQ:NUVL)May 25, 2025 | marketbeat.comTwo Sigma Investments LP Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL)May 25, 2025 | marketbeat.comNuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal yearMay 24, 2025 | investing.comTwinbeech Capital LP Invests $2.32 Million in Nuvalent, Inc. (NASDAQ:NUVL)May 24, 2025 | marketbeat.comDeutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 24, 2025 | marketbeat.comMan Group plc Purchases 41,447 Shares of Nuvalent, Inc. (NASDAQ:NUVL)May 23, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Moderate Buy" from BrokeragesMay 23, 2025 | marketbeat.comWoodline Partners LP Grows Stake in Nuvalent, Inc. (NASDAQ:NUVL)May 22, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Bank of America Corp DEMay 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVTCY, CORT, NUVL, and INDV Company DescriptionsCorcept Therapeutics NASDAQ:CORT$70.90 +0.84 (+1.20%) Closing price 04:00 PM EasternExtended Trading$70.62 -0.28 (-0.39%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Evotec OTCMKTS:EVTCY$4.27 -0.17 (-3.83%) As of 06/13/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Indivior NASDAQ:INDV$14.18 +0.29 (+2.09%) Closing price 04:00 PM EasternExtended Trading$14.52 +0.34 (+2.36%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Nuvalent NASDAQ:NUVL$76.32 -1.92 (-2.45%) Closing price 04:00 PM EasternExtended Trading$76.34 +0.03 (+0.03%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
